FDA-approved1,2Evidence: Large human trialsHormones · Sexual and reproductive health

Ganirelix1

Also called Ganirelix acetate1,2

Key takeaway

Ganirelix is a synthetic decapeptide that blocks the gonadotropin-releasing hormone (GnRH) receptor in the pituitary gland.1 FDA approved Organon’s ganirelix acetate in 1999 to prevent a premature surge of luteinizing hormone (LH) in women undergoing controlled ovarian hyperstimulation for fertility treatment.1,2 Its label describes two well-controlled studies, including a randomized trial in which 463 women received ganirelix with a GnRH agonist as the reference treatment.1

Ganirelix at a glance

What it isA synthetic decapeptide derived from natural GnRH with amino acids changed at six positions, giving it strong GnRH-blocking activity, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Organon’s ganirelix acetate, NDA 021057, with an original approval date of July 29, 1999. The cited label has no boxed warning.1,2
Human evidenceA double-blind, randomized study in 332 women and an open-label, randomized study in which 463 women received ganirelix, both described in the label.1
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is ganirelix?

Ganirelix is a synthetic decapeptide derived from natural gonadotropin-releasing hormone (GnRH), with substitutions at positions 1, 2, 3, 6, 8 and 10 that make it a strong GnRH blocker, according to the label.1

Drugs@FDA lists the original application, ganirelix acetate from Organon (NDA 021057). Other companies also hold approvals for ganirelix.2

How does ganirelix work?

The label states that ganirelix competitively blocks GnRH receptors on the pituitary, causing a rapid, reversible suppression of gonadotropin release that is more pronounced for LH than for FSH.1

What do human studies show?

The label states that effectiveness was established in two adequate and well-controlled studies in women with normal hormone and pelvic ultrasound findings, excluding women with polycystic ovary syndrome or low ovarian reserve.1

In a double-blind, randomized study of 332 women undergoing ovarian hyperstimulation for IVF, LH on the day of the final trigger fell as the amount of ganirelix increased, according to the label.1

In an open-label, randomized study, 463 women received ganirelix and the label reports their hormone levels and pregnancy outcomes alongside a GnRH agonist reference group.1

What the evidence base contains

  • Large randomized human trial Protocol 38602: a multicenter, double-blind, randomized study in 332 participants, women undergoing ovarian hyperstimulation for IVF, described in the label as one of the two studies establishing its effectiveness.1
  • Large randomized human trial Protocol 38607: a multicenter, open-label, randomized study in which 463 participants received ganirelix, with a GnRH agonist as the reference treatment, described in the label.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is ganirelix FDA-approved?

Yes. Drugs@FDA lists Organon’s ganirelix acetate, application NDA 021057, with an original approval date of July 29, 1999.2

The label cited here (DailyMed SPL version 10, published October 12, 2026) states that it is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.1

The label has no boxed warning. It is contraindicated in known or suspected pregnancy and in people allergic to GnRH or its analogues.1

Timeline

  1. FDA approves Organon’s ganirelix acetate, according to Drugs@FDA.2
  2. DailyMed publishes the ganirelix label version cited on this page.1

What is still unknown?

Its effects in women excluded from the studies, such as those with polycystic ovary syndrome or low ovarian reserve, according to the label.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Ganirelix: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Ganirelix are a bounded selection, not every registration or paper about Ganirelix. For the years before Ganirelix was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Ganirelix as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Ganirelix in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as ganirelix acetate for use in controlled ovarian hyperstimulation. The label describes two well-controlled studies, including randomized studies of 332 women and of 463 women treated with ganirelix.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Ganirelix?

FDA-approved as ganirelix acetate for use in controlled ovarian hyperstimulation. The label describes two well-controlled studies, including randomized studies of 332 women and of 463 women treated with ganirelix.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
17
Drugs@FDA applications
8

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Ganirelix?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

42Selected dated records
44Connected citations
17Populated source years1999–2026
3/4Record lanes present

Registered human studies

Trial composition

22 of 27 selected trial records include at least one phase value; 27 of 27 include a status value in the retained structured contract.

PhasesPhase 4 6Not applicable 5Early Phase 1 4Phase 2 3Phase 3 3Phase 1 2
Status at observationCompleted 24Active, not recruiting 2Recruiting 1

A phase value is unavailable here for 5 selected records; this is not counted as “no phase.”

PubMed bibliography

Publication composition

6 of 6 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 6Comparative Study 1Multicenter Study 1Review 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
8
FDA Federal Register documents
1
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
42

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 42 dated records

Research hub

Explore the Ganirelix evidence record

Open all 42 records →
42Dated records
3Evidence types
42Cited public sources
17Source years

Change ledger

Recently changed for Ganirelix

Open all 42 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00225433

PeptideScanner retained ClinicalTrials.gov record NCT00225433 at 2026-11-15T22:03:26.540Z. Its registry update date was 2015-12-03, and PeptideScanner's reviewed identity mapping was ganirelix.

PeptideScanner change date
November 15, 2026
Cited source date
December 3, 2015
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00461422

PeptideScanner retained ClinicalTrials.gov record NCT00461422 at 2026-11-15T22:03:26.540Z. Its registry update date was 2008-06-27, and PeptideScanner's reviewed identity mapping was ganirelix.

PeptideScanner change date
November 15, 2026
Cited source date
June 27, 2008
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00589134

PeptideScanner retained ClinicalTrials.gov record NCT00589134 at 2026-11-15T22:03:26.540Z. Its registry update date was 2020-03-30, and PeptideScanner's reviewed identity mapping was ganirelix.

PeptideScanner change date
November 15, 2026
Cited source date
March 30, 2020
Evidence lane
Clinical trials

Official-source collections

Source records for Ganirelix

Open the full research atlas →
PubMed6

6 with attributed title, venue, publication-date, and type metadata.

  1. New local ganirelix sustained release therapy for uterine leiomyoma. Evaluation in a preclinical organ model.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022 10 21
  2. Molecular characterization, modeling, in silico analysis of equine pituitary gonadotropin alpha subunit and docking interaction studies with ganirelix.In silico pharmacology · 2017 07 18
  3. Ganirelix for luteolysis in poor responder patients undergoing IVF treatment: a Scandinavian multicenter 'extended pilot study'.Acta obstetricia et gynecologica Scandinavica · 2010 Jun
Explore all selected literature →
ClinicalTrials.gov27

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT06745466Registry update July 2, 2026 · current at observation
  2. NCT05954962Registry update March 27, 2026 · completed at observation
  3. NCT03142893Registry update September 11, 2025 · current at observation
Explore all selected trial records →Explore all public record history →
Drugs@FDA8

Original-submission application metadata connected by exact reviewed active-ingredient names.

  1. ANDA219454Full FDA chronology · original submission status AP 2025-06-27
  2. ANDA218855Full FDA chronology · original submission status AP 2025-04-23
  3. ANDA216075Full FDA chronology · original submission status AP 2023-11-16
  4. ANDA215658Full FDA chronology · original submission status AP 2023-02-28
  5. ANDA214996Full FDA chronology · original submission status AP 2022-06-06
Explore all selected FDA applications →Explore 0 dated submissions and 0 documents for Ganirelix →

Evidence types

Coverage by source year

Selected records span July 29, 1999 to July 2, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
Dated updates connected to this profile · 42

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT06745466↗

    PeptideScanner retained ClinicalTrials.gov record NCT06745466 at 2026-11-15T22:03:26.540Z. Its registry update date was 2026-07-02, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT05954962↗

    PeptideScanner retained ClinicalTrials.gov record NCT05954962 at 2026-11-15T22:03:26.540Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  3. Literature metadata

    New local ganirelix sustained release therapy for uterine leiomyoma. Evaluation in a preclinical organ model.↗

    PubMed lists PMID 36279721 in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie as Journal Article, with publication-date metadata of 2022-10-21 (day precision). PeptideScanner associated the retained record with the identity slug ganirelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT03142893↗

    PeptideScanner retained ClinicalTrials.gov record NCT03142893 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT04037605↗

    PeptideScanner retained ClinicalTrials.gov record NCT04037605 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-09-11, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  6. Regulatory

    Drugs@FDA application ANDA219454↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 219454 with status AP dated 2025-06-27, and names ganirelix acetate among the application record's active ingredients.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT05751252↗

    PeptideScanner retained ClinicalTrials.gov record NCT05751252 at 2026-11-15T22:03:26.540Z. Its registry update date was 2025-04-27, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  8. Regulatory

    Drugs@FDA application ANDA218855↗

    The official Drugs@FDA dataset lists original submission 1 for ANDA 218855 with status AP dated 2025-04-23, and names ganirelix acetate among the application record's active ingredients.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT06091436↗

    PeptideScanner retained ClinicalTrials.gov record NCT06091436 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-12-03, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT00703014↗

    PeptideScanner retained ClinicalTrials.gov record NCT00703014 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT00702273↗

    PeptideScanner retained ClinicalTrials.gov record NCT00702273 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-09-05, and PeptideScanner's reviewed identity mapping was ganirelix.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT00988260↗

    PeptideScanner retained ClinicalTrials.gov record NCT00988260 at 2026-11-15T22:03:26.540Z. Its registry update date was 2024-08-15, and PeptideScanner's reviewed identity mapping was ganirelix.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    Ganirelix acetate injection, solution (Organon LLC) · SPL version 10 · published 2026-10-12 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: Ganirelix acetate (Organon), NDA 021057 · original approval July 29, 1999 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026